Stanley Laman Group, Ltd. Biomarin Pharmaceutical Inc Transaction History

Stanley Laman Group, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 30, 2018	SELL	$93.92 - $105.72 $5.76 Million - $6.49 Million	-61,353 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$76.01 - $99.03 $88,475 - $115,270	-1,164 Reduced 1.86%	61,353 $5.78 Million
Q1 2018 May 01, 2018	SELL	$77.67 - $92.63 $187,650 - $223,794	-2,416 Reduced 3.72%	62,517 $5.07 Million
Q4 2017 Feb 09, 2018	SELL	$80.76 - $95.13 $669,742 - $788,913	-8,293 Reduced 11.33%	64,933 $5.79 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $5.9 Million - $6.95 Million	73,226	73,226 $6.82 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.